Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2087)	11/4/2000 3:07:35 AM
From: nigel bates	Read Replies (1) \| Respond to of 4974

Can't see that they need the cash. Only conclusion I can come to is they think their stock is overvalued. nig

To: scaram(o)uche who wrote (2087)	11/6/2000 7:12:58 AM
From: nigel bates	Read Replies (1) \| Respond to of 4974

Trying harder... Nov. 6 /PRNewswire/ -- CuraGen Corporation (Nasdaq: CRGN - news), an integrated genomics based drug discovery and development company, announced today that it is making a public offering of 4 million newly issued shares of its common stock, plus up to 600,000 additional shares to cover any over-allotments. All shares of the common stock are being offered by the Company. The shares of common stock are being offered through a prospectus supplement pursuant to the Company's effective shelf registration statement in an offering jointly lead-managed by Morgan Stanley Dean Witter and Lehman Brothers, and co-managed by Dain Rauscher Wessels; Bear, Stearns & Co. Inc.; Prudential Vector Healthcare, a unit of Prudential Securities; and Thomas Weisel Partners LLC. A copy of the prospectus related to the offering can be obtained from Morgan Stanley Dean Witter at 1585 Broadway, New York, NY 10036, (212) 761-4000.